Home | Sitemap | Contact Us     Search Ranbaxy for  
  Quick Links
 
 
   
   
 
    
 
     
 
   
 
 


Home
Investor Relations > Financials > Cash Flow > Ranbaxy Laboratories Limited - Consolidated (US GAAP)
 

     Cash Flow


Untitled Document

 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(All amounts in Rupees Million, unless otherwise stated)
   
Year ended December 31,
   
2006
2005
  Cash flows from operating activities
  Net income
4,060.59
779.03
  Adjustments to reconcile net income to net cash and cash
  equivalents provided by operating activities    
  Depreciation and amortization
2,894.31
1,718.00
  Deferred income tax expense / (benefit)
764.42
(1,288.12)
  Allowance for doubtful assets
192.07
153.35
  (Gain)/loss on disposal of property, plant and equipment
(100.53)
30.06
  Loss on disposal of investments
5.57
  Income from discontinued operations
(546.60)
  Equity in gain of affiliate
(50.30)
(4.71)
  Amortization of deferred stock based compensation
358.68
32.68
  Minority interest
57.31
26.38
  Unrealised (gain) / loss on forward foreign exchange contracts
(1,092.42)
1,497.89
  Reversal for diminution in value of investments
(11.07)
  Changes in operating assets and liabilities    
  Accounts receivable
(2,623.75)
(616.84)
  Inventories
(1,750.46)
553.84
  Other current assets
(485.87)
3,144.46
  Other non-current assets
(376.93)
(226.94)
  Accounts payable
1,160.95
836.49
  Accrued expenses and other current liabilities
(702.06)
(5,062.17)
  Other non-current liabilities
989.14
344.67
  Net cash provided by operating activities
3,300.72
1,360.40
  Cash flows from investing activities    
  Purchase of property, plant and equipment
(2,778.24)
(7,858.25)
  Cash paid for acquisition of minority interest in subsidiary
(181.23)
(99.90)
  Acquisition of additional stake in equity affiliate
(673.92)
  Proceeds from sale of property, plant and equipment
119.65
110.74
  Acquisition of subsidiaries*
(14,438.73)
  Purchase of intangible assets
(690.76)
(192.44)
  Purchase of investment securities
(202.00)
  Proceed from sale of investments
33.30
  Proceed from sale of discontinued operations
1,260.10
  Amount invested in restricted cash balances
(17.25)
  Maturity of restricted cash balances
14.95
  Net cash used in investing activities
(18,155.26)
(7,438.73)
  Cash flows from financing activities
  Proceeds from borrowings from banks and financial institutions, net
856.26
10,282.12
  Proceeds from issue of foreign currency convertible bonds
19,553.60
  Principal payments on long term debt
(1,396.61)
(1,471.09)
  Principal payments on capital lease obligations
(165.63)
(0.60)
  Proceeds from issuance of term loans
1,782.95
  Payment of dividend, including tax on dividend of
Rs 444.14 million and Rs 447.55 million, respectively
(3,611.40)
(3,611.81)
  Receipt from employees on exercise of stock options
63.31
135.54
  Payment of dividend to minority stockholders in subsidiaries
(7.62)
(6.66)
  Net cash provided by financing activities
15,291.91
7,110.46
  Net increase in cash and cash equivalents during the year
437.37
1,032.14
  Effect of exchange rate changes on cash and cash equivalents
39.11
8.15
  Cash and cash equivalents at the beginning of the year
2,286.33
1,246.05
  Cash and cash equivalents at the end of the year
2,762.81
2,286.33
  Supplemental disclosures
  Cash paid during the year for interest
1,008.91
578.43
  Cash paid during the year for income taxes
845.82
841.09
  Assets under capital leases capitalized during the year
86.26
654.27
  *Acquisition of subsidiaries    
  Assets and liabilities of the subsidiaries upon acquisition    
  Working capital
893.09
  Long-lived assets other than goodwill
7,893.97
  Goodwill arising on acquisition
5,651.67
  Cost of investment in shares
14,311.42
  Direct cost
127.31
  Cash paid
14,438.73
The accompanying notes are an integral part of these consolidated financial statements.